Trial · NCT01283139
Results by group272
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 272
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4]) | Placebo | 45.4 | percentage of participants | ||
| Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4]) | Sifalimumab 200 Milligram (mg) | 58.3 | percentage of participants | ||
| Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4]) | Sifalimumab 600 mg | 56.5 | percentage of participants | ||
| Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4]) | Sifalimumab 1,200 mg | 59.8 | percentage of participants | ||
| Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants | Placebo | 42.0 | percentage of participants | ||
| Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants | Sifalimumab 200 Milligram (mg) | 57.5 | percentage of participants | ||
| Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants | Sifalimumab 600 mg | 50.0 | percentage of participants | ||
| Percentage of Participants Achieving a Positive Response in SRI (4) in 4-Gene Interferon Test High Participants | Sifalimumab 1,200 mg | 57.5 | percentage of participants | ||
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Placebo | Reduce OCS to <=7.5 mg/day: Yes | 6.5 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Sifalimumab 200 Milligram (mg) | Reduce OCS to <=7.5 mg/day: Yes | 8.2 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Sifalimumab 600 mg | Reduce OCS to <=7.5 mg/day: Yes | 9.4 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Sifalimumab 1,200 mg | Reduce OCS to <=7.5 mg/day: Yes | 6.2 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Placebo | Reduce OCS to <=7.5 mg/day: No | 93.5 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Sifalimumab 200 Milligram (mg) | Reduce OCS to <=7.5 mg/day: No | 91.8 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Sifalimumab 600 mg | Reduce OCS to <=7.5 mg/day: No | 90.6 | percentage of participants | |
| Percentage of Participants on Greater Than or Equal to 10 mg/Day Oral Prednisone (or Equivalent) at Baseline Who Were Able to Reduce to Less Than or Equal to (<=) 7.5 mg/Day | Sifalimumab 1,200 mg | Reduce OCS to <=7.5 mg/day: No | 93.8 | percentage of participants | |
Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction | Placebo | Achieved >=4-point reduction: Yes | 48.6 | percentage of participants | |
Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction | Sifalimumab 200 Milligram (mg) | Achieved >=4-point reduction: Yes | 72.7 | percentage of participants | |
Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction | Sifalimumab 600 mg | Achieved >=4-point reduction: Yes | 57.6 | percentage of participants | |
Percentage of Participants With a Cutaneous Lupus Erythematosus Disease Activity and Severity Index (CLASI) Activity Score Greater Than or Equal to (>=) 10 at Baseline Who Achieved a >= 4-point Reduction | Sifalimumab 1,200 mg | Achieved >=4-point reduction: Yes | 73.1 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01283139/results